Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial

First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial

Colgate Active Salt redefines oral hygiene with a new and improved formula

NMPA accepts supplemental Biologics License Application for enfortumab vedotin with Keytruda for treatment of bladder cancer

If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy

Johnson Matthey sells Medical Device Components business for US$700 million to Montagu

The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol

Elegen launches Enfina DNA enhancement for rapid synthesis of highly complex DNA

Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days

Bristol Myers Squibb completes acquisition of Karuna Therapeutics

KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer

Aster’s India and GCC business separation nearing completion

The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value

Carbogen Amcis (Shanghai) completed ANVISA Audit

A five-day inspection was concluded successfully with no critical and no major observations raised

Govt. announces the revamped pharmaceuticals technology upgradation assistance scheme